Exact Sciences Corporation (EXAS)
NEUTRALFundamental
39
Preço
$-
Capitalização de Mercado
$20.03B
Parte 1 · Quanto vale a empresa
Visão Geral
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University, as well as Freenome Holdings, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balanço & Liquidez
Receita
$3.25B
Exercício encerrado em 31/12/2025
Resultado Líquido
$-208M
Exercício encerrado em 31/12/2025
Fluxo de Caixa Livre
$282M
Capital Próprio Total
$2.40B
Passivo Total
$2.53B
Rácio de Liquidez
2.43
Cobertura de Juros
-
Dívida/EBITDA
35.47
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$76.95
Preço Atual
-
Margem de Segurança
-
Intervalo de Valor Justo
$50.02 - $103.88
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
-
ROE
-8.7%
Rácio P/B
8.34
P/FCF
-
Margem Bruta
69.7%
ROIC
-4.8%
Radar de Rentabilidade
Value Creation (Economic Moat)
ROIC
-4.8%
WACC
7.1%
ROIC − WACC
-11.9 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critérios de Análise Fundamental
Aprovado (7)
- Price CAGR 22.89%
- Gross Margin 69.7%
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Revenue Growth 5Y 16.8%
- Net Margin Trend -6.4% vs -37.3%
Reprovado (9)
- ROIC -4.8%
- P/B Ratio 8.34
- CapEx intensity
- Debt/EBITDA
- DCF valuation (Unknown)
- ROE -8.5%
- Analyst Consensus 28% Buy
- Earnings Surprise avg -111.7%
- Piotroski F-Score 2/9
Indisponível (11)
- EPS data insufficient
- P/FCF NaN
- Dividend Payout NaN%
- Operating Margin NaN%
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Share Dilution (missing shares data)
Piotroski F-Score
Preocupações financeiras graves
Qualidade dos Resultados
Baixa qualidade: investigar a contabilidade
Diluição de Ações
A recomprar ações. Favorável ao acionista
Governação
Risco de Auditoria
1
Risco do Conselho
2
Risco de Remuneração
3
Risco dos Direitos dos Acionistas
4
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Latest News
Recent headlines for EXAS, sourced from Markets Gazette.
- 2/23/2026POSITIVEAbbott Laboratories Kicks Off Bond Sale for Exact Sciences Deal
Abbott Laboratories is launching a significant bond sale, in as many as eight parts, to fund its approximately $21 billion acquisition of cancer-screening company Exact Sciences Corp. This move signals Abbott's strong commitment to finalizing a strategic deal that will bolster its diagnostics portfolio. For shareholders of Exact Sciences, this development is a clear positive catalyst. Acquisitions of this magnitude are typically executed at a premium to the target's current market price, suggesting an immediate upward revaluation of the stock. Abbott's financing action validates the technology and growth potential of Exact Sciences, turning the company's intrinsic value into a tangible gain for investors as the deal progresses.
via Markets Gazette